ClinicalTrials.gg
CompletedNCT05608655DELTAUpdated Feb 20, 2024

DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis

An interventional study of DKutting LL balloon and Chocolate balloon in Femoral Artery Stenosis and Popliteal Artery Stenosis, sponsored by DK Medical Technology (Suzhou) Co., Ltd.. Completed at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by DK Medical Technology (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Enrollment
24th of 56
188 · median 145
Started
2022
with 6 others
No phase
48 of 81
21 open now
Registered
37th of 81
by date
Lead sponsor
3 of 81
DK Medical Technology (Suzhou) Co., Ltd.

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 24th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2022, is one of 48 with no phase, and was the 37th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy and Safety of DKutting Balloon Versus Chocolate Balloon in the Treatment of Femoral and Popliteal Artery Stenosis

Read the detailed description

This is a prospective, multi-center, randomized controlled, open-label, noninferior study to evaluate achievement of optimal PTA dilatation. A total of 188 patients will be enrolled from 14 sites in China. All patients enrolled will be assigned to the test group (DKutting LL balloon, n=94) and the control group (Chocolate balloon, n=94) with randomized allocation ratio of 1:1.

Primary endpoint is percentage of PTA cases in which \<30% diameter stenosis without a flow limiting dissection is achieved. A 30-day after procedure follow-up will be conducted for all 188 patients.

03

Conditions studied

  • Femoral Artery Stenosis
  • Popliteal Artery Stenosis

Keywords

  • PTA Scoring Balloon
  • Optimal Balloon Angioplasty
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-80 year-old male \& non-pregnant female
  • Patients with Arteriosclerosis Obliterans of Lower Extremities, including stenosis or osculation in femoropopliteal artery.
  • Rutherford clinical category-Becker class: 2 to 5
  • Patients understand the purpose of the study, will voluntarily participate in the study and sign . Patients are willing to undergo clinical follow-up as required by this study.
  • Digital subtraction angiography (DSA) shows femoropopliteal artery stenosis above 70%, appropriate for treatment with balloon angioplasty
  • Reference vessel diameter from 2.5 to 7mm; Total length of lesion is less than 200mm; Total length of osculation lesion is less than 100mm
  • Only one target lesion needs to be Treated. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician. The number non-target lesions are limited to maximum 3.

Exclusion criteria

Exclusion Criteria:

  • Acute or sub-acute thrombosis exist in target lesion
  • Severe calcified lesion (PACSS Grading 4)
  • Guidewire cannot cross target lesion
  • Amputation planned within 30 days
  • In-stent restenosis
  • Flow-limiting dissection (NHLBI grading: D-F) occurred in target lesion by pre-dilation
  • No other lumen-reduction devices (such as: cutting balloon, dual-wire balloon, Hawk, ELCA etc.) are treated before or after test/control group treatment.
  • Before test/control group treatment, target lesion was expanded by Antegrade Dissection Re-entry (ADR) technique.
  • Patient who cannot accept anticoagulant or antiplatelet therapy
  • Aware of patient allergic to heparin, contrast, aspirin and clopidogrel, anesthetics
  • Patients who have not completed clinical trials of other drugs or devices
  • Patients with poor compliance and unable to complete the study, which is identified by investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    DKutting

    DKutting LL Scoring Balloon, DK Medtech Co Ltd

    Device: DKutting LL balloon

  • Active comparator
    Chocolate

    Chocolate Balloon, TriReme Medical LLC

    Device: Chocolate balloon

Interventions

  • DeviceDKutting LL balloon

    After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment

  • DeviceChocolate balloon

    After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment

06

What researchers measure

Primary outcomes

  1. Achievement of Optimal PTA in Percent

    Percentage of PTA cases in which \<30% diameter stenosis without a flow limiting dissection (NHLBI grading: D-F). Residual stenosis in percent and dissection NHLBI grading are accessed by independent core-lab with Medis Suite XA based on in-procedure QCA angiography. \[0-100%, higher the better\]

    Time frame: 1 day

Secondary outcomes

  1. Device Success Rate in Percent

    Device Success defined as successful delivery to the target lesion, deployment without balloon rupture, and retrieval after procedure, as qualitatively accessed by physician. \[0-100%, higher the better\]

    Time frame: 1 day

  2. Numerical Acute Lumen Gain in mm

    In-lesion acute lumen gain defined as minimal lumen diameter (MLD) in lumen after dilatation by either arm device minus baseline MLD, as accessed by independent core-lab with Medis Suite XA based on in-procedure QCA angiography. \[0-3mm, higher the better\]

    Time frame: 1 day

  3. Technical Success Rate in percent

    Percentage of target Lesion achieved \<30% diameter stenosis without a flow limiting dissection (NHLBI grading: D-F) and No Adverse Event happened in hospital. \[0-100%, higher the better\]

    Time frame: 0-7 days

  4. Freedom from clinical-driven TLR rate in percent

    Freedom from clinical-driven target lesion revascularization 1 month post procedure \[0-100%, higher the better\]

    Time frame: 30+/-7 Days post procedure

  5. Rutherford Grading Reduction in percent

    Percentage of both groups' patent number, whose Rutherford Grading \[0-6, lower is reduced by at least 1 grade post procedure, compared with pre-procedure grade. \[0-100%, higher the better\]

    Time frame: 30+/-7 Days post procedure

  6. Freedom from Amputation above ankle rate in percent

    Percentage of both groups' patient number who is free from Amputation above ankle 1 month post procedure. \[0-100%, higher the better\]

    Time frame: 30+/-7 Days post procedure

  7. Numerical Ankle Brachial Index

    Record of both groups' patient's Ankle Brachial Index (ABI) pre/post procedure by Doppler ultrasonic stethoscope. \[ABI≤0.9: confirmed peripheral artery disease; ABI≥0.97: normal people\]

    Time frame: 0-7days

07

Study locations

14 sites
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Harbin Medical University
    Ha'erbin, Heilongjiang, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Hospital of Chengdu Traditional Chinese Medicine University
    Chengdu, Sichuan, China
  • The Third People's Hospital of Chengdu
    Chengdu, Sichuan, China
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan, China
  • China-Japan Friendship Hospital
    Beijing, China
  • Xuanwu Hospital of Capital Medical University
    Beijing, China
  • The First Affiliated Hospital of Naval Medical University
    Shanghai, China
  • Zhongshan Hospital of Fudan University
    Shanghai, China
  • Tianjin Medical University General Hospital
    Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jan 2024, 12 months.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's 12 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2022
First posted
Nov 8, 2022
StartActual
Dec 27, 2022
Primary completionActual
Jan 10, 2024
CompletionActual
Feb 4, 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05608655
Lead sponsor
DK Medical Technology (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Dec 27, 2022
Primary completion
Jan 10, 2024
Completion
Feb 4, 2024
Last update
Feb 20, 2024

Study contacts

Weiguo Fu, Dr.
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion